Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience

Atezolizumab plus bevacizumab (ATZ/BV) treatment is a combined immunotherapy consisting of immune checkpoint inhibitor (ICI) and anti-vascular endothelial growth factor monoclonal antibody, which has brought a major paradigm shift in the treatment of unresectable hepatocellular carcinoma (HCC). Gain...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogawa, Keita, Kanzaki, Hiroaki, Chiba, Tetsuhiro, Ao, Junjie, Qiang, Na, Ma, Yaojia, Zhang, Jiaqi, Yumita, Sae, Ishino, Takamasa, Unozawa, Hidemi, Kan, Motoyasu, Iwanaga, Terunao, Nakagawa, Miyuki, Fujiwara, Kisako, Fujita, Naoto, Sakuma, Takafumi, Koroki, Keisuke, Kusakabe, Yuko, Kobayashi, Kazufumi, Kanogawa, Naoya, Kiyono, Soichiro, Nakamura, Masato, Kondo, Takayuki, Saito, Tomoko, Nakagawa, Ryo, Ogasawara, Sadahisa, Suzuki, Eiichiro, Nakamoto, Shingo, Muroyama, Ryosuke, Kanda, Tatsuo, Maruyama, Hitoshi, Mimura, Naoya, Kato, Jun, Motohashi, Shinichiro, Kato, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174847/
https://www.ncbi.nlm.nih.gov/pubmed/35711837
http://dx.doi.org/10.7150/jca.71494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174847/
https://www.ncbi.nlm.nih.gov/pubmed/35711837
http://dx.doi.org/10.7150/jca.71494

Ejemplares similares